Plaque Psoriasis

Panelists talk about when they might consider switching biologics for patients with plaque psoriasis.

Experts in plaque psoriasis discuss how to select a biologic based on patient factors and comorbidities.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss their experiences with biologics used to treat plaque psoriasis.

Jerry Bagel, MD, MS, discusses the mechanism of action of biologics used in plaque psoriasis.

In the study, 77% of patients treated with the Cal/BD foam treatment were satisfied with its effectiveness, 60% were satisfied with its ease of use, and 73.9% were satisfied in terms of global satisfaction.

Dr. Jerry Bagel and physician assistant, Alexa Hetzel, comment on the burden of plaque psoriasis and what options are available for the treatment of plaque psoriasis.

Jerry Bagel, M.D., M.S. and Alexa Hetzel, M.S., PA-C discuss an overview of plaque psoriasis and how plaque psoriasis impacts quality of life.

An analysis of PSOARING 1 and 2 data show the topical therapy is efficacious across a wide spectrum of psoriatic disease and patient demographics.

An analysis suggests patients on the biologic fared better with adherence and outcomes than those on competitors including adalimumab.

New phase 3 extension data show the topical PDE-4 inhibitor provided skin clearance to a significant rate of patients with psoriasis.

Promising 2-year data for the IL-17 targeting biologic were recently presented at AAD 2022.

Exact triggers in acute urticaria and chronic urticaria are largely unknown, with the success of identifying causes of AU varying between 21-68%.

Previous research has suggested that psoriasis could affect both fecundity and fertility, leading to spontaneous abortion and ectopic pregnancy.

The current registered dosing of the therapy is 30 mg twice daily, but the analyzed dosage of 20 mg has not yet been approved.

Similarly, patients affected by alopecia areata had higher odds of developing psoriasis.

New 5-year data shows psoriasis improvement was similar among patients with and without metabolic syndrome, regardless of which dose they received.

Dr. McKinley-Grant details the new health movement that aims to stop the cycle of suffering for people of color living with psoriatic disease.

However, comorbidity risk was believed to be substantially different between the two diseases.

Elapsed time following diagnosis, naïve biologic therapy status and previous use of only 1 biologic were associated with higher persistence rates.

New 108 week data found that treatment with the biologic resulted in significant skin clearance in pediatric patients with psoriasis.

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

A consensus was reached on nearly all proposals in the eDelphi study, which members said could be used to establish a clear dosing regimen for methotrexate.

An assessment of long-term VOYAGER 1 and 2 trial data show the IL-23 biologic provides significant benefit toward skin clearance, regardless of baseline characteristics.

Clinical responses including PASI 100 and absolute PASI, and PASI ≤2 were maintained through week 96 with the biologic in patients with psoriasis, with no new safety signals identified.

The new oral medicine helped some patients with mild to moderate psoriasis achieve and sustain PASI-50 after the initial study period.